Autologous Serum Eye Drops: Safe Preparation with Closed Systems in Hospital Pharmacy
Autologous serum eye drops are a well-established therapeutic option in hospital pharmacy, backed by more than four decades of clinical evidence and growing demand. However, producing them with the guarantees that current practice requires (sterility, traceability, and regulatory compliance) calls for precise technical decisions. This article reviews their indications, mechanism of action, preparation process, and the role of closed systems in the safety and standardization of their production.
What Are Autologous Serum Eye Drops and How Do They Act on the Ocular Surface?
Autologous serum eye drops are a biological preparation derived from the patient’s own blood. After blood is drawn and allowed to clot, the serum is separated by centrifugation and formulated as eye drops, typically at a 20% concentration in normal saline.
Their mechanism of action is rooted in their biochemical similarity to natural tears. Both share a pH of 7.4 and an osmolality of around 296–298 mOsm/kg, but serum contains growth factors such as EGF, TGF-β, and NGF, as well as vitamin A, fibronectin, albumin, immunoglobulins, and neuropeptides at concentrations equal to or higher than those found in tears. These components are essential for the proliferation, migration, and differentiation of the corneal and conjunctival epithelium — functions that pharmaceutical tear substitutes cannot replicate.
The result is a lubricating, trophic, anti-inflammatory, and antimicrobial effect on the epithelial repair mechanisms. Since the activity of these factors depends on the product reaching the patient under optimal conditions of sterility and stability, packaging type and aliquoting system are critical decisions within the preparation process.
Clinical Indications for Autologous Serum Eye Drops: Severe Dry Eye, Keratitis, and Other Conditions
The most recent clinical practice guidelines, including those from the American Academy of Ophthalmology, agree that autologous serum eye drops should be reserved for cases refractory to conventional treatment. The main indications are:
- Severe aqueous-deficient dry eye disease: Sjögren’s syndrome, ocular graft-versus-host disease (oGvHD), Stevens-Johnson syndrome, and other autoimmune forms of dry eye.
- Infectious keratitis and neurotrophic keratopathy: accelerates corneal ulcer resolution and promotes re-epithelialization in difficult-to-manage keratitis, as an adjunct to antimicrobial or neuroprotective therapy.
- Persistent epithelial defect: includes neurotrophic keratopathy ulcers, recurrent corneal erosions, and post-surgical defects that fail to heal with standard treatment.
- Ocular surface reconstruction: as adjunctive therapy following amniotic membrane transplantation, limbal stem cell transplantation, or penetrating keratoplasty.
- Neuropathic ocular pain: where nerve growth factor (NGF) present in the serum contributes to the regeneration of the corneal subbasal plexus.
How Are Autologous Serum Eye Drops Prepared? Process Stages and Sterility Requirements
Preparing autologous serum eye drops is a straightforward but demanding process. Every technical decision (clotting time, centrifugation force, type of diluent, and aliquoting system) has a direct impact on growth factor concentration and the microbiological safety of the final product. Protocol variability is one of the most debated aspects in the literature and one of the strongest arguments in favor of standardization.
The process runs from blood collection in sterile anticoagulant-free tubes or bags through room-temperature clotting, centrifugation, and dilution with 0.9% saline or BSS, to aliquoting into single-dose vials. At every stage, safe preparation depends as much on protocol rigor as on the type of system used.
Microbiological safety is a factor that runs through the entire process. Because of its high protein content, serum is itself a culture medium: any unnecessary breach of the system, improper storage, or a vial left open for more than 24 hours all represent real risks. Sterility testing through aerobic and anaerobic cultures before dispensing, maintaining the cold chain (the product can be stored for up to 6 months at -20°C), and the use of closed-system preparation are the measures that uphold that safety throughout the entire cycle.

Closed vs. Open Systems for Autologous Serum Preparation: Safety, Traceability, and Standardization
The primary threat to the safety of autologous serum eye drops is microbial contamination. Due to its high protein content, serum is inherently a culture medium, and open-system protocols (even those performed in a laminar flow cabinet) show non-negligible contamination rates with skin flora.
Closed-system preparation eliminates opening points through thermoplastic sterile-welded connections (TSCD-II-type systems), maintaining system integrity from blood collection through to vial aliquoting. European centers using fully closed systems have documented zero contamination rates across more than 129,000 vials (Siller A et al. 2026), while also reducing manufacturing time by up to 45% compared to systems requiring a clean room (Kirwan S et al. 2023).
From a traceability standpoint, closed systems facilitate complete lot documentation: donor identity, collection date, centrifugation parameters, microbiological test results, and storage conditions. This traceability is a GMP requirement that hospital pharmacies already apply in other areas, such as parenteral nutrition and cytotoxic drug preparation.

Criteria for Selecting a Closed System in Hospital Pharmacy: The SoHO Regulation and Key Factors
Regulation (EU) 2024/1938 (the SoHO Regulation) establishes European quality and safety standards for all substances of human origin with clinical applications, including autologous serum eye drops and plasma. Its mandatory application begins in August 2027, by which time establishments handling blood-derived products across all member states will need to have adapted their procedures to the new framework, including unit-level traceability for each dispensed vial.
The SoHO Regulation also establishes harmonized standards to reduce the regulatory fragmentation across member states that has until now directly affected the classification and production of preparations such as autologous serum.
When selecting a system for the safe preparation of autologous serum eye drops, the technical criteria hospital pharmacies should consider include:
- Sterile sealing compatibility: vial systems must support connection via validated thermal welders.
- Freeze resistance: vial integrity down to -80°C, with minimal container-product interaction.
- Volume and ergonomics: calibrated dropper vials for accurate patient dosing.
- Fill bag compatibility: Luer lock connections allow transfer from the bag or syringe without opening the system.
- Lot traceability: labeling must include donor or patient data, composition, production date, and storage conditions.
- Adaptability to ophthalmic blood-derived products: systems compatible with both autologous serum and PRP eye drop preparation broaden the therapeutic options available through a single device.
These criteria reflect the requirements that clinical practice and the regulatory framework already demand, and they directly shape the selection of available equipment.
At Bexen Medical, we have more than 48 years of experience manufacturing and distributing medical supplies for hospital pharmacy, including solutions for the safe preparation of autologous serum eye drops, such as the Eye Drop System. This system combines the YDB bag (whose accelerated coagulation beads optimize laboratory waiting times and whose integrated antibacterial filter ensures the sterility of the final product) with the COL / COL.C kit for aliquoting and dispensing into individual vials that can be frozen down to -80°C, all within a closed circuit and without the need for a clean room or laminar flow cabinet, CE-marked and manufactured under ISO 9001, ISO 13485, and ISO 14001 standards.
For more information on compatibility with your preparation protocol, contact our team.
References
Geerling G et al. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004 Nov;88(11):1467-74. doi: 10.1136/bjo.2004.044347
Shtein RM et al. Autologous Serum-Based Eye Drops for Treatment of Ocular Surface Disease: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020 Jan;127(1):128-133. doi: 10.1016/j.ophtha.2019.08.018
Vazirani J, et al. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines. Indian J Ophthalmol. 2023 Apr;71(4):1357-1363. doi: 10.4103/IJO.IJO_2756_22
Dormann F, et al. Allogenic and autologous nondiluted serum eye drops-validation strategy compliant with good manufacturing practice. Transfus Med. 2024 Aug;34(4):319-325. doi: 10.1111/tme.13068
Kirwan S, et al. Closed system production of serum eye drops using dockable saline. Vox Sang. 2023 Sep;118(9):790-793. doi: 10.1111/vox.13494
Siller A, Schennach H, Amato M. Serum Eye Drops: Implementation, Upscaling, and Patient-Centered Care – Insights from a Blood Bank in Western Austria. Transfus Med Hemother. 2026 Jan 30. doi: 10.1159/000550756
Parlamento Europeo, Consejo de la Unión Europea. Reglamento (UE) 2024/1938 del Parlamento Europeo y del Consejo, de 13 de junio de 2024, sobre normas de calidad y seguridad de las sustancias de origen humano destinadas a su aplicación en seres humanos y por el que se derogan las Directivas 2002/98/CE y 2004/23/CE [Internet]. Diario Oficial de la Unión Europea. 2024 Jul 17;L 2024/1938 [cited 2026 Jun 15]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02024R1938-20240717